{
    "nctId": "NCT05140655",
    "briefTitle": "Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-",
    "officialTitle": "Real-world Effectiveness and Safety of a Generic Fulvestrant Alone or in Combination With Cyclin Inhibitors in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-, in Two Colombian Referral Centers",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasm Female",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Objective response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Postmenopausal women (defined as those with permanent cessation of menstruation for more than 12 months, regardless of whether their menopausal condition occurred naturally or was artificially induced), ambulatory or hospitalized\n2. Diagnosis of advanced breast cancer HR +, HER2-\n3. Positivity for hormone receptors (either estrogen, progesterone, or both).\n4. Negative for human epidermal growth factor receptor 2 (HER2).\n5. Acceptance of informed consent, if it is required by local regulatory standards.\n\nExclusion Criteria\n\n1. History of previous treatment with fulvestrant.\n2. Concomitant treatment with antitumor drugs other than cyclin inhibitors (abemaciclib, palbociclib, ribociclib).\n3. Pregnancy.\n4. Lactation.\n5. Hypersensitivity to any of the excipients included in the complete formulation of fulvestrant from Dr. Reddy's Laboratories Limited.\n6. Renal insufficiency grade 4 or 5 (creatinine clearance \\<30 ml / min / 1.73 m2 according to the classification of the National Kidney Foundation).\n7. Hepatic failure (Child-Pugh C stage).\n8. Performance status ECOG \u2265 3.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}